Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 172

Results For "IMI"

4535 News Found

Health Minister Nadda reviews Monkeypox situation and preparedness
Policy | August 19, 2024

Health Minister Nadda reviews Monkeypox situation and preparedness

Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management


Lupin receives USFDA’s tentative approval for Brimonidine Tartrate Ophthalmic Solution
Drug Approval | August 17, 2024

Lupin receives USFDA’s tentative approval for Brimonidine Tartrate Ophthalmic Solution

Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) is indicated to relieve redness of the eye due to minor eye irritations.


Pfizer and BioNTech update on mRNA-based combination vaccine program against Influenza and Covid-19
News | August 16, 2024

Pfizer and BioNTech update on mRNA-based combination vaccine program against Influenza and Covid-19

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives


Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr
News | August 15, 2024

Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr

India Business grew by 11.9% YoY to Rs. 1196.2 crore


ICMR and Panacea Biotec initiates Phase III clinical trial of DengiAll
Clinical Trials | August 15, 2024

ICMR and Panacea Biotec initiates Phase III clinical trial of DengiAll

The clinical trial will be conducted at 19 sites with 10,335 participants across India


Generative AI is a top driver for cloud investments: Wipro FullStride Cloud Report
Digitisation | August 15, 2024

Generative AI is a top driver for cloud investments: Wipro FullStride Cloud Report

Majority of organizations are looking to increase investments in public and hybrid cloud


Marksans Pharma Q1 FY25 revenue up 18%
News | August 14, 2024

Marksans Pharma Q1 FY25 revenue up 18%

Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%


Wanbury appoints Prakash Venkatraman as President of API Business
People | August 14, 2024

Wanbury appoints Prakash Venkatraman as President of API Business

He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years


Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA
Opinion | August 14, 2024

Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA

Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024